Floatz logo

Oxaliplatin

Rectum Adenocarcinoma

Sixth Affiliated Hospital, Sun Yat-sen UniversitySmall moleculePhase 3Active
BB
69/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
67/ 100
Competitive Position
73/ 100

Competitive context

39 Active assets in the Rectum Adenocarcinoma cohort.

Asset / SponsorPhaseRating
Fluorouracilum
Merck Sharp & Dohme LLC
Phase 3BBB
Irinotecan
Sixth Affiliated Hospital, Sun Yat-sen University
Phase 3BBB
Cetuximab
Sixth Affiliated Hospital, Sun Yat-sen University
Phase 3BB
Pertuzumab
SWOG Cancer Research Network
Phase 2BB
Tipiracil
Sir Run Run Shaw Hospital
Phase 2BB

View all 50 →

Same molecule, other indications

Oxaliplatin is also rated in:

exocrine pancreatic carcinomaActive
BBB
Indicative · Phase 2/3
78 / 100
View asset →
colon adenocarcinomaActive
BBB
Indicative · Phase 3
77 / 100
View asset →
colorectal neoplasmActive
BBB
Indicative · Phase 4
74 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →